Get the Stockscreener App
12.93
1.20%
-0.145
Capricor Therapeutics Inc stock is traded at $12.93, with a volume of 205.28K.
It is down -1.20% in the last 24 hours and down -16.95% over the past month.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
See More
Previous Close:
$13.07
Open:
$13.08
24h Volume:
205.28K
Relative Volume:
0.19
Market Cap:
$582.24M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-15.57
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-4.94%
1M Performance:
-16.95%
6M Performance:
+181.34%
1Y Performance:
+117.40%
1-Day Range:
$12.67
$13.42
1-Week Range:
$11.75
$13.90
52-Week Range:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
12.98 | 582.24M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.80 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.64 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.94 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.15 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.12 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition - AOL
Capricor at Leerink’s Conference: Strategic Moves in Cell Therapy By Investing.com - Investing.com UK
Rare Disease Biotech Capricor Therapeutics Announces Critical Year-End Earnings Date - StockTitan
Capricor Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025 - Nasdaq
Capricor Therapeutics to Present Fourth Quarter and Full - GlobeNewswire
Capricor Therapeutics receives FDA acceptance of BLA for deramiocel - TipRanks
Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA - Marketscreener.com
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment - Lelezard
Capricor's DMD Treatment Receives FDA Priority Review Status - StockTitan
Rhumbline Advisers Has $636,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Capricor Therapeutics to Provide Corporate Update and Participate in Investor Meetings at Leerink’s Global Healthcare Conference 2025 - Nasdaq
Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025 - GlobeNewswire
Can Capricor's DMD Treatment Breakthrough Change Rare Disease Treatment? Key Updates Coming - StockTitan
New York State Common Retirement Fund Raises Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory - Insider Monkey
Capricor Therapeutics call volume above normal and directionally bullish - TipRanks
Capricor jumps on FDA priority review for lead drug - MSN
Capricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD Therapy - Asianet Newsable
How To Trade (CAPR) - Stock Traders Daily
H.C. Wainwright maintains Buy on Capricor stock with $77 target By Investing.com - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Given “Buy” Rating at HC Wainwright - Defense World
Traders Buy Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Capricor: Further Value Unlocked With Priority Review Of Deramiocel (NASDAQ:CAPR) - Seeking Alpha
CAPR underperforms with a -11.12 decrease in share price - US Post News
Capricor Therapeutics Shares Rise on FDA Priority Review -March 04, 2025 at 10:42 am EST - Marketscreener.com
Capricor, Wave Life Sciences, EVgo - TradingView
Capricor Therapeutics stock rises on FDA priority review By Investing.com - Investing.com Canada
Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment - Marketscreener.com
Capricor Therapeutics’ Deramiocel Receives FDA Priority Review - TipRanks
Capricor Therapeutics Announces FDA Acceptance and Priority - GlobeNewswire
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy - The Manila Times
Capricor stock rises as FDA reviews DMD drug (CAPR:NASDAQ) - Seeking Alpha
FDA reviews Capricor’s DMD cardiomyopathy therapy By Investing.com - Investing.com UK
First-Ever DMD Cardiomyopathy Treatment Advances: FDA Fast-Tracks Capricor's Groundbreaking Therapy - StockTitan
Capricor Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 8.4%Time to Buy? - MarketBeat
Capricor Therapeutics Inc [CAPR] stock for 14,999,998 USD was bought by Nippon Shinyaku Co Ltd - Knox Daily
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 4.8%Should You Sell? - MarketBeat
Capricor Therapeutics (CAPR) Expected to Announce Earnings on Thursday - Defense World
Black Diamond Financial LLC Acquires New Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Is Capricor Therapeutics, Inc. (CAPR) the Best Small-Cap Growth Stock to Buy Now? - Insider Monkey
10 Best Small-Cap Growth Stocks to Buy Now - Insider Monkey
Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data (NASDAQ:CAPR) - Seeking Alpha
Trading (CAPR) With Integrated Risk Controls - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.9%Time to Sell? - MarketBeat
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.9% – Time to Sell? - Defense World
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50 - Defense World
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - MarketBeat
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
| Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
| COLLIER EARL M JR | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
30,000 |
41,700 |
56,856 |
| Musket David B | Director |
Apr 23 '24 |
Option Exercise |
1.39 |
16,156 |
22,457 |
47,692 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):